Tuberculosis News and Research

Latest Tuberculosis News and Research

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

The Vanderbilt Vaccine Research Program (VVRP) has received a contract from the National Institutes of Health (NIH) to continue its work as one of the nation's Vaccine and Treatment Evaluation Units (VTEU).

27 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

NIH program provides $22M for low- and middle-income countries to combat HIV/AIDS epidemic

A new NIH program supporting HIV-related research training will provide $22 million over five years for activities in 15 low- and middle-income countries. The Fogarty International Center's HIV Research Training Program is issuing 22 awards, which are intended to strengthen the ability of the grantee institutions to combat the HIV/AIDS epidemic, while building expertise in a particular scientific or critical research infrastructure area.

27 Sep 2013

'Jekyll-and-Hyde' protein could be potent target for developing new cancer drugs

The mood changes of a 'Jekyll-and-Hyde' protein, which sometimes boosts tumour cell growth and at other times suppresses it, have been explained in a new study led by Oxford University researchers.

27 Sep 2013

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Janssen R&D Ireland announced today it has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis against HIV infection.

25 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

24 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

The quest to end extreme poverty

World leaders will join a chorus of music legends, celebrities such as Katie Holmes and Gerard Butler, and 60,000 Global Citizens on September 28, 2013 on the Great Lawn of New York's iconic Central Park.

21 Sep 2013

Equatorial Guinea presents design for malaria vaccine trial

Equatorial Guinea's Ministry of Health and Social Security recently presented a design for a malaria vaccine trial as part of the government's efforts to improve the country's public health.

21 Sep 2013

Researchers identify new gene that may have ability to prevent HIV

A team of researchers led by King's College London has for the first time identified a new gene which may have the ability to prevent HIV, the virus that causes AIDS, from spreading after it enters the body.

19 Sep 2013

Researchers discover how Yersinia immobilizes immune system to spread within organs

Researchers at Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts have identified how one type of bacteria, Yersinia, immobilizes the immune system in order to grow in the organs of mice. To do so, the researchers extended the use of a technique and suggest that it could be used to study other bacteria that use the same or similar means of infection.

17 Sep 2013

Funding for antimicrobial resistance research projects in the UK unacceptably small, say researchers

Study of funding awarded to antimicrobial resistance research projects in the UK calls for political leadership and sustained and targeted spending.

13 Sep 2013

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Results of a new study suggest that three new diagnostic tests could each be used to successfully diagnose drug resistance in tuberculosis (TB) patients in a quarter of the time taken by the current method.

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Disease Twofer: Parkin Problem Leads To Parkinson’S And Impairs Response To TB

University of California, San Francisco researchers report that a key protein associated with Parkinson's disease also plays a major role in the destruction of the bacteria that cause tuberculosis.

5 Sep 2013

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist and tuberculosis expert Jeffery Cox, PhD.

5 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Researchers identify origin of human TB

Tuberculosis remains one of deadliest infectious diseases of humans, killing 50% of individuals when left untreated. Even today, TB causes 1-2 million deaths every year mainly in developing countries. Multidrug-resistance is a growing threat in the fight against the disease.

2 Sep 2013

Tuberculosis News and Research

Latest Tuberculosis News and Research

VVRP receives contract from NIH to continue its work as Vaccine and Treatment Evaluation Units

Group Health helps protect public from infectious diseases through nationwide network

NIH program provides $22M for low- and middle-income countries to combat HIV/AIDS epidemic

'Jekyll-and-Hyde' protein could be potent target for developing new cancer drugs

Janssen signs license agreement with PATH for early development HIV-1 medicine rilpivirine

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

JPM, Bill & Melinda Gates Foundation announces capital raise for first-of-its-kind investment product

ACR journals publish guide that provides new treatments for children with systemic JIA

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

The quest to end extreme poverty

Equatorial Guinea presents design for malaria vaccine trial

Researchers identify new gene that may have ability to prevent HIV

Researchers discover how Yersinia immobilizes immune system to spread within organs

Funding for antimicrobial resistance research projects in the UK unacceptably small, say researchers

Three rapid diagnostic tests could be used to diagnose drug resistance in TB

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Disease Twofer: Parkin Problem Leads To Parkinson’S And Impairs Response To TB

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Researchers identify origin of human TB

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Tuberculosis News and Research

Latest Tuberculosis News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in